Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:ATRA NASDAQ:CLLS NASDAQ:INBX NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.47+0.2%$3.76$1.78▼$8.33$93.59M0.98747,788 shs88,252 shsATRAAtara Biotherapeutics$15.79-1.6%$13.19$5.01▼$18.70$112.65M0.2564,848 shs55,595 shsCLLSCellectis$3.68-6.8%$3.22$1.10▼$5.48$219.54M3.1224,360 shs106,193 shsINBXInhibrx Biosciences$37.52-1.8%$29.74$10.81▼$39.27$553.63M0.51146,163 shs151,192 shsKRYSKrystal Biotech$190.78-2.6%$162.81$122.80▼$207.84$5.67B0.64292,867 shs226,727 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+0.22%-2.61%+18.88%+65.56%-45.88%ATRAAtara Biotherapeutics-1.56%+8.08%+31.04%+28.79%+70.33%CLLSCellectis-6.84%-11.75%+6.98%+57.94%+100.00%INBXInhibrx Biosciences-1.83%+7.79%+35.94%+61.72%+142.06%KRYSKrystal Biotech-2.64%+1.45%+16.64%+24.49%+6.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.47+0.2%$3.76$1.78▼$8.33$93.59M0.98747,788 shs88,252 shsATRAAtara Biotherapeutics$15.79-1.6%$13.19$5.01▼$18.70$112.65M0.2564,848 shs55,595 shsCLLSCellectis$3.68-6.8%$3.22$1.10▼$5.48$219.54M3.1224,360 shs106,193 shsINBXInhibrx Biosciences$37.52-1.8%$29.74$10.81▼$39.27$553.63M0.51146,163 shs151,192 shsKRYSKrystal Biotech$190.78-2.6%$162.81$122.80▼$207.84$5.67B0.64292,867 shs226,727 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+0.22%-2.61%+18.88%+65.56%-45.88%ATRAAtara Biotherapeutics-1.56%+8.08%+31.04%+28.79%+70.33%CLLSCellectis-6.84%-11.75%+6.98%+57.94%+100.00%INBXInhibrx Biosciences-1.83%+7.79%+35.94%+61.72%+142.06%KRYSKrystal Biotech-2.64%+1.45%+16.64%+24.49%+6.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.40Hold$19.75341.83% UpsideATRAAtara Biotherapeutics 2.50Moderate Buy$21.0033.00% UpsideCLLSCellectis 2.33Hold$6.0063.04% UpsideINBXInhibrx Biosciences 1.50ReduceN/AN/AKRYSKrystal Biotech 2.75Moderate Buy$223.0016.89% UpsideCurrent Analyst Ratings BreakdownLatest KRYS, CLLS, INBX, ATRA, and ADVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025CLLSCellectisWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingPositive$4.0010/17/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$224.0010/17/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $8.0010/17/2025KRYSKrystal BiotechBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$182.00 ➝ $255.0010/9/2025ADVMAdverum BiotechnologiesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold10/8/2025ADVMAdverum BiotechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ATRAAtara BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025CLLSCellectisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025INBXInhibrx BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025KRYSKrystal BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025ADVMAdverum BiotechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell ➝ Sell (D-)(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M93.78N/AN/A$3.40 per share1.31ATRAAtara Biotherapeutics$128.94M0.86N/AN/A($16.89) per share-0.93CLLSCellectis$56.30M3.63N/AN/A$2.36 per share1.56INBXInhibrx Biosciences$200K2,716.45$113.70 per share0.33$9.23 per share4.07KRYSKrystal Biotech$359.21M15.37$4.51 per share42.26$32.90 per share5.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)ATRAAtara Biotherapeutics-$85.40M-$0.43N/AN/AN/A3.07%-8.34%6.61%11/11/2025 (Estimated)CLLSCellectis-$36.76M-$0.82N/AN/AN/A-100.69%-68.05%-21.53%11/3/2025 (Estimated)INBXInhibrx Biosciences$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.9238.7818.93N/A40.85%15.21%13.81%11/3/2025 (Estimated)Latest KRYS, CLLS, INBX, ATRA, and ADVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025INBXInhibrx Biosciences-$2.94N/AN/AN/AN/AN/A11/11/2025Q3 2025ATRAAtara Biotherapeutics-$0.83N/AN/AN/A$2.74 millionN/A11/3/2025Q3 2025ADVMAdverum Biotechnologies-$1.80N/AN/AN/AN/AN/A11/3/2025Q3 2025CLLSCellectis-$0.10N/AN/AN/A$8.22 millionN/A11/3/2025Q3 2025KRYSKrystal Biotech$1.04N/AN/AN/A$93.72 millionN/A8/13/2025Q2 2025INBXInhibrx Biosciences-$2.92-$1.85+$1.07-$1.85N/A$1.30 million8/12/2025Q2 2025ADVMAdverum Biotechnologies-$2.24-$2.34-$0.10-$2.34N/AN/A8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32$0.19+$0.51$0.19$4.23 million$17.58 million8/4/2025Q2 2025CLLSCellectis-$0.15-$0.24-$0.09-$0.24$10.07 million$18.19 million8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A1.541.54ATRAAtara BiotherapeuticsN/A1.701.70CLLSCellectis0.581.381.38INBXInhibrx Biosciences1.454.984.98KRYSKrystal BiotechN/A9.689.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%ATRAAtara Biotherapeutics70.90%CLLSCellectis63.90%INBXInhibrx Biosciences82.46%KRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%ATRAAtara Biotherapeutics4.00%CLLSCellectis16.41%INBXInhibrx BiosciencesN/AKRYSKrystal Biotech13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.98 million19.73 millionOptionableATRAAtara Biotherapeutics3307.02 million6.74 millionOptionableCLLSCellectis29055.58 millionN/AOptionableINBXInhibrx Biosciences16614.48 millionN/AOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableKRYS, CLLS, INBX, ATRA, and ADVM HeadlinesRecent News About These CompaniesMutual of America Capital Management LLC Purchases 1,926 Shares of Krystal Biotech, Inc. $KRYS2 hours ago | marketbeat.comTD Asset Management Inc Has $2.76 Million Position in Krystal Biotech, Inc. $KRYS3 hours ago | marketbeat.comKrystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025October 21 at 11:14 AM | markets.businessinsider.comKrystal Biotech’s FDA Platform Designation Pushes Limits of the AwardOctober 21 at 11:14 AM | biospace.comBKrystal Biotech, Inc. to Report Third Quarter 2025 Financial Results on November 3, 2025October 21 at 8:31 AM | quiverquant.comQPrivium Fund Management B.V. Purchases 1,810 Shares of Krystal Biotech, Inc. $KRYSOctober 21 at 6:04 AM | marketbeat.com91,099 Shares in Krystal Biotech, Inc. $KRYS Bought by William Blair Investment Management LLCOctober 21 at 4:27 AM | marketbeat.comJanney Montgomery Scott LLC Lowers Stock Holdings in Krystal Biotech, Inc. $KRYSOctober 20 at 4:20 AM | marketbeat.comKrystal Biotech (NASDAQ:KRYS) Price Target Raised to $255.00October 20 at 2:07 AM | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Shares Gap Up Following Analyst UpgradeOctober 19 at 2:23 AM | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Shares Gap Up After Analyst UpgradeOctober 18, 2025 | marketbeat.comBank of America Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock PriceOctober 18, 2025 | marketbeat.comExpert Outlook: Krystal Biotech Through The Eyes Of 9 AnalystsOctober 17, 2025 | benzinga.comKrystal Biotech price target raised to $255 from $182 at BofAOctober 17, 2025 | msn.comB of A Securities Maintains Krystal Biotech (KRYS) Buy RecommendationOctober 17, 2025 | msn.comBlair William & Co. IL Has $667,000 Stake in Krystal Biotech, Inc. $KRYSOctober 17, 2025 | marketbeat.comKrystal Biotech And 2 More Growth Stocks With Significant Insider OwnershipOctober 16, 2025 | finance.yahoo.comFDA’s Second Platform Designation Goes to Krystal After Sarepta WithdrawalOctober 15, 2025 | biospace.comBAberdeen Group plc Grows Stock Position in Krystal Biotech, Inc. $KRYSOctober 15, 2025 | marketbeat.comKrystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic KeratitisOctober 14, 2025 | markets.businessinsider.comQ3 EPS Estimates for Krystal Biotech Cut by William BlairOctober 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRYS, CLLS, INBX, ATRA, and ADVM Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$4.47 +0.01 (+0.22%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$4.38 -0.09 (-1.99%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Atara Biotherapeutics NASDAQ:ATRA$15.79 -0.25 (-1.56%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$15.76 -0.02 (-0.16%) As of 10/21/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Cellectis NASDAQ:CLLS$3.68 -0.27 (-6.84%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$3.67 -0.01 (-0.27%) As of 10/21/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Inhibrx Biosciences NASDAQ:INBX$37.52 -0.70 (-1.83%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$37.63 +0.11 (+0.29%) As of 10/21/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Krystal Biotech NASDAQ:KRYS$190.78 -5.18 (-2.64%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$187.64 -3.14 (-1.65%) As of 10/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
